Driving data collated by Samsara shows that while long haul transportation and food and beverage sectors have essentially reached pre-COVID-19 commercial driving activity, other industries, like transit, education, and oil and gas are far from recovery. ...
ETF.com Managing Editor Cinthia Murphy joins Yahoo Finance's Melody Hahm to break down the retail ETFs to watch after May retail sales increased a seasonally adjusted 17.7%....
New coronavirus cases continue to spike around the globe, leading health and government officials in Austin, Texas, to extend stay-at-home orders, while Beijing announces it will close down schools and certain sectors of the economy again. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round. ...
Amarin (AMRN) is seriously undervalued, according to Cantor analyst Louise Chen.On Monday, the drug maker presented encouraging new data from the REDUCE-IT study. After taking 4g a day of Vascepa, Amarin’s high triglycerides treatment, diabetes patients experienced a 23% drop in both first and total primary composite major adverse cardiovascular events. Chen thinks this data underscores Vascepa's “continuing commercial success and future potential.”“We believe the news is important because it is the first time that data specific to the diabetes population has been presented. Included for example was that in the diabetic patients treated in REDUCE-IT more than half of such patients were already on two or more drugs for diabetes and over 90% were on at least one such medicine. This emphasized that the Vascepa results were incremental to the lowering of A1C and other impacts of such medicines,” the analyst said.Sales of Vascepa, Amarin’s only product, have been hit...
